KYV-101 anti-CD19 CAR-T cell therapy
70408
Phase 1 mab active
Quick answer
KYV-101 anti-CD19 CAR-T cell therapy for Multiple Sclerosis is a Phase 1 program (mab) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kyverna Therapeutics
- Indication
- Multiple Sclerosis
- Phase
- Phase 1
- Modality
- mab
- Status
- active